Health Care·Biotechnology·$5.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | -104.42% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.74 | N/A | -104.42% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current market dynamics impacting results. They highlighted a commitment to strategic initiatives despite the setbacks.
Management acknowledged the challenging market conditions affecting performance.
They emphasized ongoing efforts to improve operational efficiency.
This earnings report indicates that Apellis Pharmaceuticals is facing significant challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 5.91%, likely due to investor concerns about the company's current performance and lack of guidance. The absence of revenue figures further adds to the uncertainty surrounding the company's outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025